Raymond James Financial’s ImmuCell ICCC Stock Holding History

Raymond James Financial’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,970	Closed	-$13.7K	–	5779
2025 Q2	$13.7K	Buy	+1,970	New	+$11.5K	﹤0.01%	5765

Other funds holding ICCC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Raymond James Financial's ICCC Position: Q3 2025 in Review

Raymond James Financial sold out of ImmuCell (ICCC) in Q3 2025, closing a stake of 1,970 shares — an estimated $13.7K sold.

Raymond James Financial first reported a position in ICCC in Q2 2025 and held it in 1 quarter. The position peaked at $13.7K in Q2 2025. 27 funds tracked by Wall St. Rank hold ICCC as of Q3 2025.

Raymond James Financial reported no remaining ImmuCell position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 1,970 ImmuCell shares in Q3 2025, an estimated $13.7K.
Raymond James Financial first reported a position in ImmuCell in Q2 2025 and held it in 1 quarter.
Raymond James Financial's ImmuCell position peaked at $13.7K in Q2 2025.
27 funds tracked by Wall St. Rank held ImmuCell as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.